108results about How to "Reduce and prevent formation" patented technology

Disclosed herein are methods and compositions for treating or preventing Huntington's Disease.

The present invention relates to alkylglycoside-containing compositions and methods for increasing the stability, reducing the aggregation and immunogenicity, increasing the biological activity, and reducing or preventing fibrillar formation of a peptide, polypeptide, or variant thereof, for example insulin and Peptide T or analog thereof.

A system and method are provided for preventing damage to the epidermis or other epithelial or non-target tissue during photodynamic therapy treatment. For example, an inhibiting radiation can be used to control formation of a photosensitizer from a precursor photosensitizer in the epidermis or epithelial tissue. Subsequent application of a treatment radiation can activate the photosensitizer to damage or destroy target sites while the non-target tissue remains substantially unaffected.

The present invention relates to compositions and methods employing a water soluble magnesium compound. In certain embodiments, the composition includes water and water soluble magnesium compound, but lacks other materials commonly used in cleaning compositions. The methods and compositions can provide magnesium ion at predefined ratios to calcium ion in water, such as magnesium ion in a molar amount equal to or in excess over a molar amount of calcium ion. A water soluble magnesium salt including an anion of a water soluble calcium salt is more effective than a magnesium salt with an anion of a water insoluble calcium salt. These compositions can be used for reducing lime scale or precipitate formation from hard water, removing soap scum, or the like.

The invention relates to structured water and its antioxidant activity. In addition, the present invention relates to antioxidants incorporated within the cluster structure of either electropositive (S water) or electronegative (I water). The structured water, having the antioxidant within its cluster structure, has a stabilizing effect on the antioxidant. In addition, the antioxidant activity inherent to structured water is enhanced by the presence of the antioxidant within its cluster structure. The present invention also includes methods of removing or reducing free radicals on the skin and thereby preventing the signs of skin aging and the risks of cancer associated with the presence of free radicals in the skin.

Provided herein is a placental membrane product comprising an immunocompatible chorionic membrane. Such placental membrane products can be cryopreserved and contain therapeutic factors and viable cells after thawing. The placental membrane products are useful in wound healing or tissue repair/regeneration as they are capable of promoting angiogenesis, reducing inflammation, reducing scar formation, and other methods that promote healing. The present technology relates to products to protect injured or damaged tissue, or as a covering to exclude bacteria, to inhibit bacterial activity, or to promote healing or growth of tissue. The field also relates to methods of manufacturing and methods of use of such membrane-derived products.

Provided herein is a placental membrane product comprising an immunocompatible amniotic membrane. Such placental membrane products can be cryopreserved and contain therapeutic factors and viable cells after thawing. The placental membrane products are useful in wound healing and tissue repair/regeneration as they are capable of promoting angiogenesis, reducing inflammation, inhibiting proteases and free radical oxidation, reducing scar formation, and other methods that promote healing. The present technology relates to products to protect injured or damaged tissue, or as a covering to prevent adhesions, to exclude bacteria, to inhibit bacterial activity, and/or to promote healing or growth of tissue. The field also relates to methods of manufacturing and methods of use of such membrane-derived products.

The invention is based on a correlation observed between visceral fat and gut flora. The invention relates to a product increasing the relative proportion of bifidobacteria in the intestines and to be used for preventing formation of visceral fat or for reducing the amount thereof in the body. In particular, the product increases the ratio of bifidobacteria to Clostridia. The invention also relates to determining visceral fat in the body by determining the relative proportion of bifidobacteria or Clostridia or their ratio to each other in the intestines. The invention further relates to a method for estimating, in the same manner, the health risk associated with obesity.

The present invention is directed towards a composition comprising, in an aqueous medium: (a) at least one anti-dandruff agent; (b) at least one viscosity modifying agent; (c) at least acrylic-based polymeric compound different from the viscosity modifying agent; (d) at least two surfactants chosen from amphoteric surfactants and zwitterionic surfactants; and (e) optionally, at least one conditioning agent. The present invention also relates to a process for the care of hair and/or scalp.

The present invention relates to the use of plasminogen/plasmin and its derivatives as agents for enhancing host defense against infection or other infectious diseases. The invention also relates to a method for screening of compounds which enhance host defense against infection by evaluating the host defense against bacterial arthritis and spontaneous otitis media in an animal model.

The present invention provides synthetic immunogenic lipopeptide molecules comprising co-linear T-helper and B cell epitopes, and methods for their production and use in the generation of primary and secondary immune responses, and for the vaccination of animal subjects against particular antigens. More particularly, the present invention provides highly soluble lipopeptides wherein the lipid moiety is attached to the terminal side-chain group of an internal lysine or lysine analog, preferably to the terminal side-chain group of an internal diamino acid residue. Preferably the internal lysine or lysine analog is positioned between the T-helper epitope and the B cell epitope or within the T-helper epitope.

Disclosed are compositions and methods for their use that include a combination of hydrolyzed algin, escin, Ruscus aculeatus root extract, ammonium glycyrrhizate, Centella asiatica extract, hydrolyzed yeast protein, and Calendula officinalis flower extract.

The invention relates to a stable pharmaceutical composition comprising comprising a solid dispersion of tacrolimus in a vehicle further comprising a stabilizing agent capable of providing a pH below 7 in the composition, as measured after re-dispersion in water, and preventing or reducing the formation upon storage of major degradation products of tacrolimus, in particular the 8-epitacrolimus.

Reducing or preventing adhesions which would form in a patient during or after surgery by administering to the wound surface of a patient a fibrinogen solution in an amount of about 0.025 ml fibrinogen/cm² to about 0.25 ml fibrinogen/cm² of the surface being at risk for developing adhesions. User of fibrinogen in a preparation comprising fibrinogen at a concentration of 20 to 80 mg/ml for the reduction or prevention of post-surgical adhesion formation.

A method for preventing the formation of contaminating polymeric films on the backsides of semiconductor substrates includes providing an oxygen-impregnated focus ring and/or an oxygen-impregnated chuck that releases oxygen during etching operations. The method further provides delivering oxygen gas to the substrate by mixing oxygen in the cooling gas mixture, maintaining the focus ring at a temperature no greater than the substrate temperature during etching and cleaning the substrate using a two step plasma cleaning sequence that includes suspending the substrate above the chuck.